Cargando…

Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance

Cefiderocol is a new siderophore-cephalosporin for the treatment of multi-drug resistant Gram-negative pathogens. As a reserve agent, it will and should be used primarily in critically ill patients in the upcoming years. Due to the novelty of the substance little data on the pharmacokinetics in crit...

Descripción completa

Detalles Bibliográficos
Autores principales:	König, Christina, Both, Anna, Rohde, Holger, Kluge, Stefan, Frey, Otto R., Röhr, Anka C., Wichmann, Dominic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226704/ https://www.ncbi.nlm.nih.gov/pubmed/34071700 http://dx.doi.org/10.3390/antibiotics10060649

Ejemplares similares

Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649
por: König, Christina, et al.
Publicado: (2021)

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol
por: Zimmer, Julia, et al.
Publicado: (2021)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
por: Zahr, Noël, et al.
Publicado: (2022)

1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients
por: Katsube, Takayuki, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting
por: Perea, José Ramón Azanza, et al.
Publicado: (2022)

Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series
por: Mornese Pinna, Simone, et al.
Publicado: (2022)

Posaconazole exposure in critically ill ICU patients: a need for action
por: König, Christina, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
por: Katsube, Takayuki, et al.
Publicado: (2019)

Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia
por: Katsube, Takayuki, et al.
Publicado: (2021)

Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
por: Kobic, Emir, et al.
Publicado: (2021)

Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
por: Viale, Pierluigi, et al.
Publicado: (2023)

Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx)
por: Alraish, Rawan, et al.
Publicado: (2020)

Daptomycin Pharmacokinetics in Blood and Wound Fluid in Critical Ill Patients with Left Ventricle Assist Devices
por: Calov, Stefanie, et al.
Publicado: (2023)

Influence of microbiological diagnosis on the clinical course of spondylodiscitis
por: Stangenberg, Martin, et al.
Publicado: (2021)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

Excessive unbound cefazolin concentrations in critically ill patients receiving veno-arterial extracorporeal membrane oxygenation (vaECMO): an observational study
por: Booke, Hendrik, et al.
Publicado: (2021)

Erratum to: Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia
por: Katsube, Takayuki, et al.
Publicado: (2021)

Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations
por: Katchanov, Juri, et al.
Publicado: (2018)

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
por: Chiriac, Ute, et al.
Publicado: (2023)

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
por: Katsube, Takayuki, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
por: Wenzler, Eric, et al.
Publicado: (2021)

Epidemiology, clinical characteristics, and outcome of candidemia in critically ill patients in Germany: a single-center retrospective 10-year analysis
por: Schroeder, Maria, et al.
Publicado: (2020)

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

Correction to: Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
por: Wenzler, Eric, et al.
Publicado: (2022)

Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment
por: Chiriac, Ute, et al.
Publicado: (2021)

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
por: Bonomo, Robert A
Publicado: (2019)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

Clinical experience of cefiderocol
por: Fariñas, María Carmen
Publicado: (2022)

Mechanism of action of cefiderocol
por: Soriano, Alex, et al.
Publicado: (2022)

Cefiderocol. Summary and conclusions
por: Mensa, José, et al.
Publicado: (2022)

Antibacterial spectrum of cefiderocol
por: Cordero, Desirée Gijón, et al.
Publicado: (2022)

739. Prediction of Cefiderocol Pharmacokinetics and Probability of Target Attainment in Pediatric Subjects for Proposing Dose Regimens
por: Katsube, Takayuki, et al.
Publicado: (2019)

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens
por: Pybus, Christine A, et al.
Publicado: (2019)

Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
por: Palermo, Gabriele, et al.
Publicado: (2023)

Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing
por: Chiriac, Ute, et al.
Publicado: (2021)

Ciprofloxacin in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): A Population Pharmacokinetic Study
por: Alihodzic, Dzenefa, et al.
Publicado: (2022)

The role of cefiderocol in clinical practice
por: Maseda, Emilio, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
por: Saisho, Yutaka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t2eig3gcqptffm6k9ph30s4e1g